Overview

A Study in Rheumatoid Arthritis

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of multiple doses of LY2439821 in Japanese patients with rheumatoid arthritis.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Ixekizumab